Days after closing its nearly $4 billion Gambro acquisition, Baxter has snatched up a tiny Israeli startup for what amounts to pocket change in comparison.
Big Pharma companies are fighting to stay out of the spotlight as authorities show up to visit them.
The FDA has sent Baxter International a warning letter laying out problems it found during inspections at a plant in North Carolina as well as at a plant in Jayuya, Puerto Rico.
Baxter International's sales of infusion pumps and related equipment grew moderately in the 2013 first quarter, reflecting slow growth in the company as a whole.
Baxter International ($BAX) is grabbing a hemophilia A candidate in late-stage development from partners whose collaboration ran aground last year.
Baxter International reports that its pivotal Phase III study comparing routine preventive use versus on-demand treatment using its anti-inhibitor coagulant complex FEIBA NF for hemophilia passed with flying colors, setting up plans to file for an approval soon.
Baxter is reportedly within two weeks of throwing down $4 billion to snatch up Gambro AB, a Swedish maker of kidney dialysis machines.
Onconova Therapeutics has scored a major partnership deal with Baxter International ($BAX), which has ponied up $50 million upfront and committed $515 million in potential milestones for European market rights to Onconova's anti-cancer drug rigosertib now in late-stage development for rare blood cancers and a Phase II/III trial for patients with pancreatic cancer.
The SEC wants to see Baxter International's financial records on the recalls of its Colleague and Syndeo infusion pumps back in 2010, which were pulled from shelves by the FDA.
Boston Scientific's ($BSX) Q1 earnings numbers dazzled Thursday as it reported net income of $113 million, or $0.08 per share--a big jump from $46 million, or $0.03 per share, during the same period last year.